ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/NZ/0622-Takapuna-North-Shore-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
14
trial(s) found.
NCT06943872
Haem
Phase 3
Recruiting
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (
BGB-11417-303
)
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2217 - Kogarah - St George Hospital
2480 - Lismore - Lismore Base Hospital
2500 - Wollongong - Wollongong Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6005 - West Perth - Perth Blood Institute
6168 - Cooloongup - Rockingham Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06846671
Haem
Phase 3
Recruiting
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors (
CaDAnCe-302
)
BTK PROTAC degrader
Bcl2 inhibitor
PI3K delta inhibitor
alkylating agent
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4350 - Toowoomba - Toowoomba Hospital
WA
6005 - West Perth - Perth Blood Institute
NZ
NZ.0622 - Takapuna - North Shore Hospital
NCT06742996
Haem
Phase 3
Recruiting
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma (
BGB-11417-302
)
BTK inhibitor
Bcl2 inhibitor
placebo
Mantle cell lymphoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6005 - West Perth - Perth Blood Institute
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - One Clinical Research
6168 - Cooloongup - Rockingham Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
NCT06634589
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies (
BGB-16673-104
)
BTK PROTAC degrader
B-cell lymphoma
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06508658
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (
EPCORE-DLBCL-4
)
anti-CD20 monoclonal antibody
antimetabolite
bispecific T-cell engager,CD20-targeting
immunomodulatory imide drug
platinum-based antineoplastic agent
Diffuse large B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4350 - Toowoomba - Toowoomba Hospital
WA
6000 - Perth - Royal Perth Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT06351631
Haem
Phase 3
Recruiting
A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study (
3543-017
)
LSD1 inhibitor
Myelofibrosis
Polycythemia vera
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Gold Coast University Hospital
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06136559
Haem
Phase 3
Recruiting
A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (
1026-011
)
BTK inhibitor
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (COMPLETED)
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NCT06079879
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) Versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia Who Have an Inadequate Response to or Are Intolerant of Hydroxyurea (
3543-006
)
LSD1 inhibitor
antimetabolite
Essential thrombocythaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05020236
Haem
Phase 3
Recruiting
AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR (
MAGNETISMM-5
)
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3121 - Richmond - Epworth Freemasons Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Greenslopes Private Hospital
4217 - Benowa - Pindara Private Hospital
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT04920617
Haem
Phase 2
Recruiting
A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (
VITALIZE
)
alkylating agent
anti-PD-1 monoclonal antibody
cell therapy,T-cell immunotherapy
Diffuse large B-cell lymphoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3128 - Box Hill - Box Hill Hospital - Eastern Health
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NCT04771130
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies (
BGB-11417-103
)
Bcl2 inhibitor
Acute myeloid leukaemia
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Gold Coast University Hospital
WA
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - One Clinical Research
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT04170283
Haem
Phase 3
Enrolling by invitation
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies (
BGB-3111-LTE1
)
BTK inhibitor
B-cell malignancy
NOT Solid tumour
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Border Medical Oncology Research Unit
ACT
2606 - Canberra - Paratus Clinical Research Woden
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Brisbane Clinic For Lymphoma, Myeloma And Leukaemia
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.3210 - Hamilton - Waikato Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT03229200
Haem
Phase 4
Enrolling by invitation
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials. (
PCYC-1145-LT
)
BTK inhibitor
Leukaemia
Lymphoma
Solid tumour
NA
2025 - Papatoetoe - Middlemore Hospital
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.0622 - Takapuna - North Shore Hospital
NCT02966756
Haem
Phase 2
Recruiting
A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (
M14-728
)
Bcl2 inhibitor
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
VIC
3168 - Clayton - Monash Medical Centre
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (12)
Enrolling by invitation (2)
Recruitment Country and State
NZ (14)
VIC (13)
NSW (12)
QLD (10)
WA (9)
SA (5)
ACT (2)
TAS (1)
Phase
Phase 1 / Phase 2 (2)
Phase 2 (2)
Phase 3 (9)
Phase 4 (1)
Trial Type
Haem (14)
Cancer Therapy Class
Bcl2
43%
BTK
43%
CD20
29%
cereblon
14%
LSD1
14%
PD-1
14%
PD-1/PD-L1
14%
PI3K delta
7%
JAK1
7%
JAK2
7%
BCMA
7%
CD38
7%
DNA methyltransferase
7%
Facility
NZ.0622 - Takapuna - North Shore Hospital (14)
3168 - Clayton - Monash Medical Centre (10)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (8)
2217 - Kogarah - St George Hospital (6)
3004 - Melbourne, Southbank - Alfred Health (6)
2139 - Concord - Concord Repatriation General Hospital (6)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (5)
3000 - Melbourne - Peter MacCallum Cancer Centre (4)
3065 - Fitzroy - St Vincent's Hospital Melbourne (4)
4102 - Woolloongabba - Princess Alexandra Hospital (4)
3128 - Box Hill - Box Hill Hospital - Eastern Health (4)
6009 - Nedlands - Linear Clinical Research (4)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (4)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (4)
6005 - West Perth - Perth Blood Institute (3)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (3)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (3)
2050 - Camperdown - Chris O'Brien Lifehouse (3)
6000 - Perth - Royal Perth Hospital (3)
NZ.3210 - Hamilton - Waikato Hospital (3)
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
6168 - Cooloongup - Rockingham Hospital (2)
4350 - Toowoomba - Toowoomba Hospital (2)
6009 - Nedlands - One Clinical Research (2)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (2)
4215 - Southport - Gold Coast University Hospital (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
3002 - East Melbourne - Epworth Freemasons (2)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (2)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
5042 - Bedford Park - Flinders Medical Centre (2)
2109 - North Ryde - Macquarie University Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2480 - Lismore - Lismore Base Hospital (1)
2500 - Wollongong - Wollongong Private Hospital (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
2500 - Wollongong - Wollongong Hospital (1)
2605 - Garran - The Canberra Hospital (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
2170 - Liverpool - Liverpool Hospital (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
3066 - Epping - Northern Hospital (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
2606 - Canberra - Paratus Clinical Research Woden (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
4120 - Greenslopes - Brisbane Clinic For Lymphoma, Myeloma And Leukaemia (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
7000 - Hobart - Royal Hobart Hospital (1)
2025 - Papatoetoe - Middlemore Hospital
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
Cancer Type
Cancer
Haematological malignancy
B-cell malignancy
Lymphoma
B-cell lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Leukaemia
Chronic lymphocytic leukaemia
Lymphoid leukaemia
Small lymphocytic lymphoma
Myeloproliferative neoplasm
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Mantle cell lymphoma
Myelofibrosis
Polycythemia vera
Essential thrombocythaemia
Multiple myeloma
Plasma cell disorder
Acute myeloid leukaemia
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
Myeloid leukaemia
Solid tumour
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy